GANATON OD 150mg

Land: India

Taal: Engels

Bron: Central Drugs Standard Control Organization

Werkstoffen:

ITOPRIDE

Beschikbaar vanaf:

Abbott

Dosering:

150MG

farmaceutische vorm:

OD CAP

Samenstelling:

10

Bijsluiter

PRODUCT NAME
Itopride Hydrochloride in sustained release form
BRAND NAME
Ganaton OD
DESCRIPTION
Itopride hydrochloride is an orally active
gastroprokinetic agent. Ganaton OD is a film-coated
slow release tablet containing itopride hydrochloride
150 mg.
INDICATIONS
Ganaton OD is indicated for the treatment of
gastrointestinal symptoms caused by reduced
gastrointestinal motility, like feeling of fullness, upper
abdominal pain, anorexia, heartburn, nausea and
vomiting; non-ulcer dyspepsia or chronic gastritis.
DOSAGE AND ADMINISTRATION
ADULTS
The usual dose of itopride hydrochloride for adult
patients is 150 mg daily before meals. The dose may
be reduced according to the patient’s age and
symptoms (see PRECAUTIONS).
DURATION OF TREATMENT
In clinical studies, itopride hydrochloride has been
administered up to 8 weeks.
CONTRAINDICATIONS
Itopride hydrochloride is contraindicated in patients
with known hypersensitivity to itopride hydrochloride
or any of the excipients.
Itopride hydrochloride should not be used in patients
in whom an increase in gastrointestinal motility could
be harmful, e.g. gastrointestinal hemorrhage,
mechanical obstruction or perforation.
WARNINGS AND PRECAUTIONS
GENERAL
Itopride hydrochloride enhances the action of
acetylcholine and may produce cholinergic side
effects.
Data on long-term use are not available.
PEDIATRIC USE
Safety of itopride in children under the age of 16 has
not been established.
GERIATRIC USE
In general, appropriate caution should be exercised in
the administration and monitoring of itopride
hydrochloride in elderly patients reflecting the greater
frequency of decreased hepatic, renal function, and of
concomitant disease or other drug therapy.
DRUG INTERACTIONS
Metabolic interactions are not expected since itopride
is primarily metabolized by flavine monooxygenase and
not by CYP450.
No changes in protein binding have been seen with
coadministration of warfarin, diazepam, diclofenac
sodium, ticlopidine hydrochloride, nifedipine, and
nicardipine hydrochloride.
Since itopride h